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Ecdysteroids, analogs of the insect molting hormone, are known for their various mild, nonhormonal bioactivities in mammals.
Previously, we reported that less-polar ecdysteroids canmodulate the doxorubicin resistance of amultidrug resistant (MDR)mouse
lymphoma cell line expressing the human ABCB1 transporter. Here, we describe the ability of 20-hydroxyecdysone (1) and its
mono- (2) and diacetonide (3) derivatives to sensitize variousMDR and non-MDR cancer cell lines towards doxorubicin, paclitaxel,
vincristine, or cisplatin. Drug IC
50
values with or without ecdysteroid were determined by MTT assay. Compound 3 significantly
sensitized all cell lines to each chemotherapeutic except for cisplatin, whose activity was decreased. In order to overcome solubility
and stability issues for the future in vivo administration of compound 3, liposomal formulations were developed. By means of
their combination index values obtained via checkerboard microplate method, a formulation showed superior activity to that of
compound 3 alone. Because ecdysteroids act also on non-ABCB1 expressing (sensitive) cell lines, our results demonstrate that they
do not or not exclusively exert their adjuvant anticancer activity as ABCB1 inhibitors, but other mechanisms must be involved, and
they opened the way towards their in vivo bioactivity testing against various cancer xenografts.
1. Introduction
Ecdysteroids represent a particularly interesting group of
natural compounds from several aspects, with functions in all
kingdoms of nature: in insects, they play a crucial hormonal
role controlling molting and development [1]; in plants, they
appear to serve as part of the chemical defense against
nonadapted herbivores [2]; and, although with a less-studied
and unclear role, they are also present in fungi [3]. These
compounds show fundamental differences to themammalian
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steroid hormones, which make them unable to interact with
their hormonal system [4]. Despite this, a number of rather
beneficial metabolic effects have been attributed to them
in mammals including humans: a mild anabolic activity of
ecdysteroids undoubtedly exists [4], and these compounds
can also influence both glucose and lipid homeostasis [5],
altogether resulting in a so-called adaptogenic or “antistress”
effect.
The role of ecdysteroids in cancer is yet to be understood.
In accordance with their “general strengthening” effect on
mammals, in vitro antiapoptotic effect of muristerone A was
observed in RKO human colon carcinoma cells [6]. As a
result of a thorough study onmany natural and semisynthetic
ecdysteroids, we have recently reported that certain deriva-
tives can significantly decrease the doxorubicin resistance
of a multidrug resistant (MDR) mouse lymphoma cell line
(L5178MDR) that has been transfected with the pHa MDR1/A
retrovirus to express the humanABCB1 or P-glycoprotein, an
ATP-binding cassette (ABC) transporter [7]. Mild to strong
synergism with doxorubicin was found for the less-polar
derivatives, while classical, polar ecdysteroids, such as, for
example, 20-hydroxyecdysone (20E; 1), could act in a weak
antagonism or indifferent way with this chemotherapeutic
agent [7]. Our following structure-activity relationship stud-
ies revealed that the introduction of apolar groups at the
20,22 and particularly at the 2,3 position is of key importance
in order to have a sensitizing effect on doxorubicin in the
aforementioned cell line [7–9]. Interestingly, although several
of the less-polar ecdysteroids could inhibit the function of
ABCB1, this inhibition was moderate or negligible and only
a very marginal correlation to the strength of synergism with
doxorubicin could be found [7].
Two derivatives of 20E (1), 20-hydroxyecdysone 20,22-
acetonide (2), and 20-hydroxyecdysone 2,3;20,22-diace-
tonide (3) are of particular interest in our studies; structures
of these three compounds are shown in Figure 1.
Compounds 2 and 3 can also be found in the nature but
their semisynthetic preparation from the abundant 20E (1) is
extremely simple and economic; moreover, compound 3 was
among the most active ecdysteroids in our previous studies
[7–9]. In fact, compounds 1–3 represent good examples for
the different levels of activity of ecdysteroids in L5178MDR
cells from theweak antagonism to the strong synergismwhen
coadministered with doxorubicin, which makes these three
compounds an ideal choice to further study the effects of
ecdysteroids in cancer and also the mechanism by which
they exert their activity. On the other hand, the well-known
acid sensitivity of acetonide groups (resulting in a quick
decomposition of compound 3 to compound 2 at gastric pH
[7]) and solubility problems, mainly of compound 3, could
be an impediment to further in vivo studies. This fact made
further formulations necessary prior to performing animal
studies.
Nanosized drug delivery systems, such as liposomes, are
potential carriers for the encapsulation of bioactive agents,
both hydrophilic and hydrophobic molecules, peptides, and
so forth. Synthetic and natural phospholipids and cholesterol
derivatives are important components of the biocompatible,
Table 1: Composition of liposome samples LIP-1, LIP-2, and LIP-3.
Components LIP-1 (mol%) LIP-2 (mol%) LIP-3 (mol%)
Compound 3 9 8 8
L-PC 44 24 25,9
Lecithin 21 15 16
C-24 7 12 12,8
b-DG 3 7 0
PEG-3000 PE 0 0 0,3
Cholesterol 16 34 37
less immunogenic, and nontoxic liposomes [10, 11]. Con-
trolled or targeted drug release and reduction of the number
and strength of side effects are the main advantages.
In the present paper, we report the investigation of com-
pounds 1–3 in combination with various chemotherapeutic
agents against a panel of different drug-sensitive and drug-
resistant cancer cell lines, as well as the development of a
liposomal formulation of compound3 in order to allow future
in vivo studies.
2. Materials and Methods
2.1. Chemicals and Reagents. 20E (90% purity, originating
from the roots of Cyanotis arachnoidea) was purchased
from Shaanxi KingSci Biotechnology Co. Ltd. (Shanghai,
China) and further purified by crystallization to possess
97.8% purity; this served as the starting material for
the semisynthesis of compounds 2 and 3 as published
before [8]. Phosphatidylcholines as L-alpha phosphatidyl-
choline and lecithin and 1,2-distearoyl-sn-glycero-3-phos-
phoethanolamine-N-[methoxy(polyethylene glycol)-3000]
(ammonium salt) as PEG-3000 PE were purchased from
Avanti Polar Lipids Inc. (US). Cholesterol, polyoxyethylene-
24-cholesterly ether, beta-D-glucopyranoside, anhydrous
ethanol, sodium chloride, and sodium phosphate buffer
salt (Na
2
HPO
4
⋅2H
2
O) were purchased from VWR Int. Ltd.
(Austria). PES syringes and membrane syringe filters with
pore sizes of 100, 220, and 900 nm and a diameter of 25mm
were purchased from Phenomenex Inc. (Gen-Lab Ltd.,
Hungary).
2.2. Preparation of Liposomes. Liposomes were prepared by
the hydration of thin dry lipid filmmethod.The compositions
usedwere selected according to a preliminary preformulation
study (in preparation). Briefly, L-alpha phosphatidylcholine
(L-PC), cholesterol, lecithin, polyoxyethylene-24-cholesterly
ether (C-24), and beta-D-glucopyranoside or PEG-3000 PE
were solubilized together with compound 3 in anhydrous
ethanol at 65∘C; compositions of formulae LIP-1, LIP-2, and
LIP-3 are shown in Table 1. Polyoxyethylene-24-cholesterly
ether, beta-D-glucopyranoside (b-DG), and cholesterol were
used to stabilize the liposome bilayer. The PEG-3000 PE
was used as material for PEGylation of the liposomes. The
solvent was later removed by evaporation on a rotary vacuum
evaporator (Bu¨chi RotavaporR-210 System, Bu¨chi Labortech-
nik, Switzerland) at 𝑝 = 150mbar. The lipid film layer
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Figure 1: The structures of compounds 1, 2, and 3.
was rehydrated in filtered (100 nm) phosphate buffer saline
solution (pH 7.4) having the osmolality of 279mOsm/L. The
liposome dispersion was kept in a refrigerator at 4∘C for 2 h
prior to the droplet size reduction. The process was achieved
by sonicating the liposome dispersion for 15min at 100%
amplitude (Elma TH075EL Ultrasonic bath, ELMAGmbH&
Co. KG, Germany). Liposomes of uniform size were prepared
by filtration (membrane filters, PES) once through 900 and
220 nm pore size filters. Sorbic acid (0.05% w/v) was added
to the buffer solution in order to ensure microbiological
stability.
2.3. Determination of the Average Hydrodynamic Size and
Surface Electric Charge of LiposomeDispersion. The liposome
dispersion was characterized for average droplet size, poly-
dispersity index (PDI, representing size distribution), and
surface electric charge by DLS (dynamic laser scattering)
method with a Zetasizer Nano ZS (Malvern Instruments
Ltd., UK). The optical parameters (i.e., refractive index of
the dispersion and the buffer solution) and the conductivity
were measured before the DLS measurement. The liposomes
were stored at 25∘C for 1 h prior to analysis and then diluted
with ultrapure water. Liposomes were measured after 1 week
storage time, which is enough to observe the possible phase
separation (i.e., the conflux of liposome droplets) that could
be caused by any undesirable alteration of the preparation
process (𝑛 = 3).
2.4. Quantitative Analysis of Compound 3 within Liposomes.
0.5mL of LIP-1, LIP-2, or LIP-3 was measured into a 5.0mL
volumetric flask, diluted to 1.5mL with HPLC-gradient water
and adjusted to 5.0mL with HPLC grade methanol. HPLC
analysis was performed on a system of two Jasco PU-2080
pumps connected to a Jasco MD-2010 Plus photodiode-
array detector, in isocratic mode by 70% aqueous methanol
on a Zorbax XDB-C8 column (5 𝜇m, 4.6 × 150mm) at a
flow rate of 1.5mL/min at 𝜆 = 243 nm. Each measurement
was performed in triplicates, as well as the calibration that
was performed by injecting 0.2, 0.5, 1.0, 3.0, and 5.0 𝜇g of
compound 3.
2.5. Cell Lines. Six human derived cancer cell lines were used
in this study: breast cancer MCF7 cells and their subcell
line obtained by adaptation to doxorubicin, MCF7dox [12]
cultured in EMEM media supplemented with nonessential
amino acids, 1mM Na-pyruvate, and 10% inactivated fetal
bovine serum (MCF7dox was cultured in the presence of
1 𝜇M of doxorubicin each third passage); prostate cancer
cells PC3 and LNCaP cultured in RPMI 1640 media supple-
mented with 10% inactivated fetal bovine serum; in case of
LNCaP medium also contained 1mM Na-pyruvate, HEPES,
and glucose; epidermal carcinoma cell line KB-3-1 and its
subline KB-C-1 obtained by stepwise adaption to colchicine
(generously donated by D.W. Shen, Bethesda, USA) cultured
in RPMI 1640 media supplemented with 10% inactivated
fetal bovine serum. All cells were cultured at 37∘C and
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5% CO
2
; all media contained nystatin, 2mM L-glutamine,
100U penicillin, and 0.1mg streptomycin.
Twomouse lymphoma cell lineswere also used: a parental
(L5178) cell line, L5178mouse T-cell lymphoma cells (ECACC
catalog number 87111908, U.S. FDA, Silver Spring, MD, U.S.),
and a multidrug resistant (L5178MDR) cell line derived from
L5178 by transfection with pHa MDR1/A retrovirus [13].
Cells were cultured in McCoy’s 5A media supplemented
with nystatin, L-glutamine, penicillin, streptomycin, and
inactivated horse serum, at 37∘C and 5% CO
2
. MDR cell
line was selected by culturing the infected cells with 60𝜇g/L
colchicine (Sigma).
Media, fetal bovine serum, horse serum, and antibiotics
were purchased from Sigma.
2.6. Cytotoxicity Assays
Cytotoxic Activity. Cytotoxic activities were evaluated by
serial-dilution method in 96-well flat-bottom microtiter
plates. In case of L5178 and L5178MDR cell lines, 6 × 10
3
cells were added to each well and results were evaluated
using 10% MTT after 72 h incubation at 37∘C, 5% CO
2
. In
case of PC3 and LNCaP cell lines, 1 × 104 cells were added
to each well and results were evaluated using 10% MTT
after 48 h. With respect to the MCF7, MCF7DOX, KB-3-1,
and KB-C-1 cell lines, 1 × 104 cells per well were seeded
overnight and serial dilutions of the compound were added
the following day and incubated for 48 h or 72 h. In all cases,
the precipitate formed in the MTT reaction was diluted with
10% SDS-HCl after 4 h. Plates were incubated overnight and
optical density was measured at 540 and 630 nm using an
ELISA reader (Multiskan EX, Lab Systems, U.S.). Fifty per
cent inhibitory concentrations (IC
50
) were calculated using
nonlinear regression curve fitting of log(inhibitor) versus
normalized response and variable slope with a least squares
(ordinary) fit of GraphPad Prism 5 software.
2.7. Combination Studies at Fixed Ecdysteroid Concentration.
As compounds 1–3 were found to exert very low cytotoxicity
activity on each cell line (see below), the activity of 50𝜇M
of compound on the IC
50
of doxorubicin (Teva), paclitaxel
(Mayen) cisplatine (Teva), or vincristine was tested using the
same protocol as described above to the cytotoxicity testing
for the respective cell lines. In each case, statistical analysis
was carried out by one-way ANOVA with Bonferroni’s post
hoc test, and differences were considered significant at ∗𝑃 <
0.05, ∗∗𝑃 < 0.01, and ∗∗∗𝑃 < 0.001. In order to prevent any
possible false positive results and strengthen the relevance of
our data for possible in vivo studies, we also set up a stricter
criterion: statistically significant potentiation was considered
relevant only when at least a two-time decrease in the IC
50
of the chemotherapeutic agent was observed. Such measures
were not applied in case of an antagonistic effect (see results
for cisplatin).
2.8. Combination Studies with Liposomes Containing Com-
pound 3. The combined activity of doxorubicin (Teva) and
formulations LIP-1, LIP-2, and LIP-3 on the L5178MDR mouse
lymphoma cells was determined using the checkerboard
microplatemethod in 96-well flat-bottommicrotiter plates as
published before [7]. Briefly, 1 × 104 cells/well were incubated
with different concentrations of doxorubicin and liposomes
containing compound 3 for 48 h at 37∘C under 5% CO
2
.
Cell viability rate was determined through MTT staining,
and the interaction was evaluated by using the CompuSyn
software (CompuSyn, Inc., U.S.) for the constant liposome
versus doxorubicin ratios. Combination index (CI) values are
presented for 50%, 75%, and 90% of growth inhibition. In
each case, the amounts of liposomes were applied so that
they represent the same amount of compound 3within, based
on the results of the quantitative determination by HPLC
(see above, Section 2.4). As such, M/M ratios of compound 3
versus doxorubicin were used to calculate the results, which
was performed according to that suggested by Chou [14].
3. Results and Discussion
Our previous observations on the strong activity of com-
pound 3, a less-polar ecdysteroid, against the doxorubicin
resistance ofABCB1 expressingMDRmurine lymphoma cells
[7] led to the need of a thorough study on these compounds
using various human cell lines and chemotherapeutics. The
chosen cell lines included drug susceptible/MDR cell line
pairs, such as the previously used L5178 and the ABCB1 trans-
fected L5178MDR (mouse lymphoma), MCF7 and its ABCB1
expressing subcell line MCF7dox adapted to doxorubicin
(mammary gland), and KB-3-1 and its ABCB1 expressing
subcell line KB-C-1 adapted to colchicine (cervix). Two
prostate cancer cell lines were also used in our experiments,
the steroid dependent LNCaP and the nonsteroid dependent
PC3. When tested alone on these cell lines, compounds 1, 2,
and 3 exerted very low cytotoxic activities with IC
50
values
of typically >100 𝜇M, except for compound 3 on the L5178
(81.12 ± 5.5 𝜇M) and compound 2 on the MCF7 cell line
(89.67 ± 4.1 𝜇M).
The effect of 50 𝜇M of compounds 1–3 was tested on
the cytotoxic activity of chemotherapeutics with distinct
mechanisms of action, such as doxorubicin (topoisomerase
II inhibitor, ABCB1 substrate), paclitaxel (stabilizes micro-
tubule polymer, ABCB1 substrate), vincristine (antitubulin
agent on tubulin dimers, ABCB1 substrate), and cisplatin
(alkylating agent, non-ABCB1 substrate); results are shown in
Figure 2.
It is important to mention that even though compounds
1–3 exert negligible intrinsic cytotoxic activity at the applied
concentration of 50𝜇M, this approach is still a simplification
as compared to an appropriate calculation of synergism, for
example, by using the checkerboard plate method [14], and,
as such, it could lead to false positive results. Considering
this and also taking into account our previous observations
on the IC
50
patterns in combination studies on checkerboard
plates [7], we decided to accept only those results as actual
sensitizing activity, where at least a two-time decrease in the
IC
50
value of the chemotherapeutic could be observed.
Compound 3 exerted a significant sensitization effect
on all cell lines when applied together with doxorubicin,
vincristine, or paclitaxel. Results with doxorubicin could not
be determined on the highly resistant MCF7dox cell line
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Figure 2: The effect of 50 𝜇M of 1, 2, or 3 on the IC
50
values of chemotherapeutics in various susceptible and MDR cell lines. ∗𝑃 < 0.05,
∗∗
𝑃 < 0.01, and ∗∗∗𝑃 < 0.001 bymeans of one-wayANOVA followed by Bonferroni post hoc test as compared to that of the chemotherapeutic
agent alone (C); n.r.: statistically significant, but not relevant sensitization.
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Table 2: Droplet size characteristics and encapsulation efficiency of compound 3 within liposome samples LIP-1, LIP-2, and LIP-3 (𝑛 = 3).
Liposome
samples
Average hydrodynamic
size [nm]
Droplet size
distribution
Polydispersity
index (PDI)
Surface electric
charge [mV]
Entrapment
efficiency (%)
LIP-1 92.1 ± 0.5 30–300 nm (100%) 0.16 −2.16 ± 0.77 43%
LIP-2 83.2 ± 0.9 20–200 nm (100%) 0.16 −2.46 ± 0.45 8%
LIP-3 84.7 ± 1.3 20–220 nm (100%) 0.19 −1.37 ± 0.56 50%
since that chemotherapeutic agent had to be applied in such
high doses that the measurements were disturbed by its
own color (data not shown); paclitaxel resistance of this
cell line could also not be reverted. Altogether, the results
that are in agreement with those observed by us previously
and strongly support our previous assumption [7] that less-
polar ecdysteroids do not or not exclusively act as ABCB1
inhibitors: compound 3 could effectively sensitize non-MDR
human cell lines with no detectable (MCF7 [12, 15], KB-3-1
[16, 17]) or very low (LNCaP [18]) expression of the ABCB1
protein, as well as the drug-sensitive mouse lymphoma cell
line (L5178). Moreover, the IC
50
of doxorubicin in the L5178
cell line and itsABCB1 transfected counterpart L5178MDR was
decreased to practically the same values, 41.7 and 45.6 nM,
respectively (no significant difference by unpaired 𝑡-test), in
the presence of 50 𝜇M of compound 3, while the IC
50
values
for doxorubicin alone on the L5178 and the L5178MDR cell
lines were 228.3 and 3537 nM, respectively. Compound 3 was
also able to reduce the paclitaxel resistance of PC3 cells to
the same level of those of untreated LNCaP cells (IC
50
= 44.8
and 63.5 nM, resp. and no significant difference by unpaired
𝑡-test), while the treatment of LNCaP cells with compound
3 led to an even stronger cytotoxic activity of paclitaxel
(IC
50
= 16.5 nM). Moreover, KB-3-1 cells were sensitized by
compound 3 to vincristine in a way that it reached much
lower IC
50
values than observed in KB-C-1 cells treated
with the combination: the IC
50
value was 0.67 nM (without
compound 3: 2.84 nM) in case of KB-3-1, while it was ca. 10
times higher, 6.78 (without compound 3: >50 nM) in case of
the MDR subline KB-C-1. A comparison of these values also
reveals that resistance of KB-C-1 cells to vincristine could
not completely be reverted by compound 3: even though a
strong sensitizing activity was observed, the cytotoxicity of
vincristine was still significantly weaker than in the parental
KB-3-1 cell line (𝑃 < 0.001 by unpaired 𝑡-test).
The 20,22-acetonide compound (2) showed tendencies
for an activity pattern similar to the diacetonide 3, but
with much weaker and in several cases irrelevant activities.
Interestingly and somewhat unexpectedly, compound 1, 20-
hydroxyecdysone, was also found to show significant and
relevant sensitizing activity in case of one cell line, MCF7,
when coadministered with paclitaxel.
On the other hand, the tested ecdysteroids showed an
obvious general tendency to decrease the activity of cisplatin
in all cell lines, especially in the two breast cancer cells lines
(MCF7 and MCF7dox) where all compounds significantly
elevated its IC
50
values. In case of the two prostate carci-
noma cell lines, the compounds showed different behaviors:
only compound 3 could significantly protect the steroid
dependent LNCaP cells from the effect of cisplatin, while
compounds 1 and 2 exerted such an activity in the PC3
cells where compound 3 did not influence the efficacy of
cisplatin. Although androgen hormone dependency is a
major difference between these two cell lines, it should be
noted that ecdysteroids do not exert androgenic activity [4].
Relevance of our results in terms of a possible interference
with actual chemotherapy with cisplatin in cancer patients
will have to be clarified by further studies; considering the
large number of food supplements containing high amounts
of ecdysteroids (mainly compound 1) available on themarket,
the possibility of unwanted interactions cannot be excluded.
On the other hand, Konovalova et al. have previously found
that 10mg/kg of compound 1 could potentiate the activity
and decrease the toxicity of cisplatin in P388 leukemia or
B16 melanoma bearing mice, and the authors suggested
that beneficial metabolic and immune system modulatory
effects of this compound might be the reason for this
phenomenon [19]. Such mechanisms could indeed overwrite
an otherwise antagonistic effect observed in our experimental
in vitro setup. Nevertheless, the strong potentiating activity of
compound 3 on the activity of doxorubicin, vincristine, and
paclitaxel on various cell lines is highly promising.
As the next step towards animal experiments, the slight
acid sensitivity of compound 3 (resulting in its decomposition
to compound 2 with a half-life of ca. 7.30min at gastric
pH [7]), as well as solubility problems attributed to this
compound needed to be solved; in order to fulfill these
objectives, liposomal formulations were developed.
The average hydrodynamic size and surface electric
charge (zeta potential) parameters of liposome samples of
various lipid compositions are shown in Table 2. The droplet
size and the PDI values are typical of SUV (small unilamellar
vesicle) type liposomes, ranging from 83 to 92 nm and from
0.16 to 0.19, respectively. One size fraction of liposomes was
observed in the range of 20–220 or 20–300 nm, irrespective
of the lipid composition used for the preparation. A slight
increase in the zeta potential from −2.16 (LIP-1) and −2.46
(LIP-2) mV to the value of −1.37mV (LIP-3) was observed
with the addition of PEG-PE lipid.
Encapsulation of compound 3 into LIP-1, LIP-2, and
LIP-3 resulted in entrapment efficiencies of 43, 8, and 50%,
respectively (Table 2). LIP-1 and LIP-2 represent different
compositions, containing more L-PC and lecithin (LIP-1) or
more cholesterol and C-24 (POE-cholesteryl-ether) (LIP-2).
Cholesterol andC-24were used as bilayer stabilizers, but their
increased concentration was not enough to achieve complete
droplet stability for LIP-2. However, the compositions of LIP-
2 and LIP-3 are rather similar; the difference is the addition of
the PEG-3000 PE component in the latter case. The increase
of the entrapment efficiency from 8% to 50% could be due to
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Figure 3: Fa-CI plots of the nonformulated compound 3 and that enclosed within liposomes (LIP-1, LIP-2, and LIP-3) tested on the L5178MDR
cell line. Concentrations correspond to compound 3/doxorubicin ratio of 20.4M/M in each case. Fa = fraction affected. Dashed horizontal
line shows CI = 1, and CI < 1, CI = 1, and CI > 1 represent synergism, additivity, and antagonism, respectively. The error bars show 95%
confidence intervals by means of serial deletion analysis. In the table, CI values are presented at 50%, 75%, and 90% of inhibition (ED
50
, ED
75
,
and ED
90
, resp.); CIavg = (CI50 + 2CI75 + 3CI90)/6;𝐷𝑚,𝑚, and 𝑟 represent antilog of the x-intercept, slope, and linear correlation coefficient of
the median-effect plot, respectively. These parameters indicate the activity (IC
50
), shape of the dose-effect curve, and conformity of the data,
respectively [7]; ∗: significantly stronger synergism with doxorubicin as compared to compound 3 by means of nonoverlapping confidence
intervals.
the fact that the exact average molecular weight of PEG-3000
PE material is around tenfold higher (3772.36) than those of
the other components. This relatively high molecular weight
could ensure better physicochemical stability and therefore a
much higher entrapment of compound 3 [20].
In order to investigate the activity of the liposomes
containing compound 3 in comparison with that of the
nonformulated compound, interactions between LIP-1, LIP-
2, and LIP-3 and doxorubicin were tested on checkerboard
plates. This experimental setup was chosen because in these
complex systems there were too many factors that could have
influenced the results, and hence we decided not to apply the
simplification presented above. Synergism/antagonism was
quantified by using the CompuSyn software as in our previ-
ous work [7, 9]. Quantitative determination of compound 3
within the formulations allowed us to apply the same doses in
each case, as expressed in compound 3 equivalents. Results of
these experiments are shown in Figure 3.
Based on our results, the formulations not only keep the
strong synergistic activity of compound 3 and doxorubicin,
but also, particularly in case of LIP-3, are able to show
favorable activity as compared to the free compound. The
slight increase in the potentiating activity might be explained
by the liposomes ability to fuse with the cell membranes and
deliver the enclosed compound to the cells more efficiently
even in vitro; however, the favorable effect on the solubility
of compound 3 in the aqueous environment can also be
among the reasons for this phenomenon. It is also important
to note that the acidic pH of around 5 maintained within
the lysosomes [21] (that compound 3 likely faces upon the
phagocytosis of the liposomes) is apparently not enough to
hydrolyze the acetonide groups, which could have been a
serious pitfall for these formulations if compound 3 would
decompose to the much less active compound 2 [7].
4. Conclusions
We demonstrated that the 20,22-acetonide (2) and in par-
ticularly the 2,3;20,22-diacetonide (3) derivatives of 20-
hydroxyecdysone (1) are able to exert sensitizing activity to
doxorubicin, paclitaxel, and vincristine in MDR cell lines,
which express the ABCB1membrane transporter, as well as in
their susceptible counterparts. Even though, in this work, no
conclusions can bemade about themechanism(s) of action of
these compounds, these results strongly support our previous
assumptions [7] that these ecdysteroids do not or not only act
as ABCB1 inhibitors when exerting their adjuvant anticancer
activity.
Moreover, all ecdysteroids showed significant protective
effects towards cisplatin treatment on some of the cell lines
tested in vitro, highlighting the importance of further studies
in this direction.
Compound 3 enclosed in liposomes (LIP-3) showed
stronger synergistic activity in combinationwith doxorubicin
on L5178MDR cells as compared to the case when it was
applied in solution. Based on these results, LIP-3 represents
8 BioMed Research International
a highly prospective formulation for in vivo studies. Such
studies have most recently started within our research pro-
gram; results are going to be presented in the near future.
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